搜索监管参考资料 | 药品
正文 · 中文译文
查找监管参考资料 | 药品 CDER小型企业与行业援助（SBIA） 关于CDER小型企业与行业援助（SBIA） CDER SBIA学习 查找监管参考资料 | 药品 CDER SBIA按需学习库 使用筛选器和搜索框查找监管资源 主题 关于FDA和CDER；生物制品、生物类似药、生物制品许可申请（BLA）；临床试验、药物开发与批准；合规、检查、执法；配制；数据库；药物主文件；药物安全、召回；药物供应链；仿制药、简化新药申请（ANDA）；进口/出口、监管事务、国际项目；试验用新药申请（IND）；标签；会议、与FDA沟通；新药审评、新药申请（NDA）；非处方药审评；药品质量与生产；上市后活动和推广；罕见病和孤儿药；注册与登记；法规、法律、指南；报告；提交、表格、联系人；培训资源；用户费用 清除筛选 名称主题 供应链药物供应链 查找药品质量文件药品质量与生产 多终点指南摘要法规、法律、指南；临床试验、药物开发与批准 涉及儿童的临床研究中的伦理考虑——指南摘要法规、法律、指南；临床试验、药物开发与批准 新生儿指南摘要法规、法律、指南；临床试验、药物开发与批准 以患者为中心的药物开发临床结局评估 指南 概览：法规、法律、指南；临床试验、药物开发与审批 食物影响指南概览：法规、法律、指南；临床试验、药物开发与审批 生物利用度指南概览：法规、法律、指南；临床试验、药物开发与审批 群体药代动力学指南概览：法规、法律、指南；临床试验、药物开发与审批 病理学同行评审指南概览：法规、法律、指南；临床试验、药物开发与审批 新药和生物制品的获益-风险评估概览：法规、法律、指南；临床试验、药物开发与审批 协变量校正指南概览：法规、法律、指南；临床试验、药物开发与审批 体外药物相互作用研究指南概览：法规、法律、指南；临床试验、药物开发与审批 临床药物相互作用研究指南概览：法规、法律、指南；临床试验、药物开发与审批 复杂创新试验设计指南概览：法规、法律、指南；会议、与FDA互动 最大使用量试验指南概览：法规、法律、指南；临床试验、药物开发与审批 靶向治疗指南概览：法规、法律、指南；临床试验、药物开发与审批 多重终点指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 涉及儿童的临床研究中的伦理考虑——指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 新生儿研究指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 以患者为中心的药物开发临床结局评估 指南回顾 播客文字记录法规、法律、指南；临床试验、药物开发与审批 食物影响指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 生物利用度指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 群体药代动力学指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 病理学同行评审指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 协变量调整指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 体外药物相互作用研究指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 临床药物相互作用研究指南回顾播客文字记录法规、法律、指南；临床试验、药物开发与审批 复杂创新性试验设计指南回顾播客文字记录；法规、法律、指南；会议、与FDA沟通 复杂仿制药新闻；仿制药、简化新药申请 新兴技术计划；药品质量与生产 肿瘤学监管专业知识和早期指南（OREEG）；临床试验、药物开发与批准、研究性新药开发申请（IND）、会议、与FDA沟通 OTC专论@FDA；非处方药审评 非处方药（OTC）审评 | 《CARES法案》中的OTC专论改革；非处方药审评 语音和正字法计算机分析（POCA）计划；药物安全；临床试验、药物开发与批准 关于CDER小企业与行业援助；关于FDA和CDER 关于FDA；关于FDA和CDER CDER独占权委员会；关于FDA和CDER CDER监察员；关于FDA和CDER 与FDA开展业务；关于FDA和CDER FDA职位；关于FDA和CDER 生物类似药开发、审评与批准；生物制品、生物类似药、生物制品许可申请（BLA） 生物类似药产品信息（FDA批准的生物制品清单）；生物制品、生物类似药、生物制品许可申请（BLA） 生物类似药；生物制品、生物类似药、生物制品许可申请（BLA） 生物类似药行动计划；生物制品、生物类似药、生物制品许可申请（BLA） 生物类似药行业信息和指南；生物制品、生物类似药、生物制品许可申请（BLA） 《BPCI法案》的“视为许可条款”；生物制品、生物类似药、生物制品许可申请（BLA） 关于治疗性生物产品的常见问题——生物制品、生物类似药、生物制品许可申请（BLA） 治疗性生物制品申请（BLA）批准信息——生物制品、生物类似药、生物制品许可申请（BLA） 治疗性产品转入CDER（药品评价与研究中心）——生物制品、生物类似药、生物制品许可申请（BLA） 紫皮书：已许可生物制品清单及参照产品独占期、生物类似性或可互换性评价——生物制品、生物类似药、生物制品许可申请（BLA）；数据库 生物类似药用户付费修正案（BsUFA）——生物制品、生物类似药、生物制品许可申请（BLA）；用户付费 生物标志物资格认定程序——临床试验、药物开发与批准 组合产品——临床试验、药物开发与批准 临床试验与人类受试者保护——临床试验、药物开发与批准 开发与批准流程——临床试验、药物开发与批准 药物开发与药物相互作用：底物、抑制剂和诱导剂表——临床试验、药物开发与批准 药物开发流程——临床试验、药物开发与批准 FDA药品审评流程：确保药品安全有效——临床试验、药物开发与批准 药物开发的经济援助与激励措施——临床试验、药物开发与批准 冠状病毒（COVID-19）——临床试验、药物开发与批准 COVID MyStudies应用程序（App）——临床试验、药物开发与批准 关于专利和独占性的常见问题 临床试验、药物开发与审批 真实世界证据 临床试验、药物开发与审批 合规行动与活动 合规、检查、执法 检查、合规、执法和刑事调查 合规、检查、执法 未经批准的药物 合规、检查、执法 致制药公司的警告信和违规通知信 合规、检查、执法 配制和FDA：问答 配制 配制风险警报 配制 配制：检查、召回和其他行动 配制 人类药物配制 配制 药物批准和数据库 数据库 Drugs@FDA 数据库 FDALabel 数据库 非活性成分数据库 数据库 国家药品代码目录 数据库 药品短缺 数据库 搜索延长使用日期列表以协助应对药品短缺 数据库 经治疗等效性评价批准的药品（橙皮书） 数据库；仿制药、简略新药申请（ANDA） 药物主文件网页 药物主文件 药物主文件：指南 药物主文件 用于活性药物成分的II型DMF 药物主文件 药物主文件（DMF）的类型 药物主文件 药品召回 药品安全、召回 药品安全通讯 药品安全、召回 FDA不良事件报告系统（FAERS）公共仪表板 药品安全、召回 Medwatch 药品安全、召回 可预防的药物不良反应：关注药物相互作用 药品安全、召回 风险评估与缓解策略（REMS）；药物安全，召回 药物安全标签变更；药物安全，召回；标签 FDA不良事件报告系统（FAERS）电子提交；药物安全，召回；提交，表格，联系人 行业Medwatch报告；药物安全，召回；提交，表格，联系人 药物安全与可及性；药物安全；数据库 药物供应链完整性；药物供应链 药物供应链安全法案；药物供应链 核实批发药品分销商许可证；药物供应链 简化新药申请（ANDA）；仿制药，简化新药申请（ANDA） 评估2017年仿制药用户收费修正案下的用户费用：行业指南；仿制药，简化新药申请（ANDA） 溶出方法数据库；仿制药，简化新药申请（ANDA） 首批仿制药批准；仿制药，简化新药申请（ANDA） 仿制药研究相关指南和报告；仿制药，简化新药申请（ANDA） 仿制药：行业信息；仿制药，简化新药申请（ANDA） 仿制药指南文件（在主题下搜索“仿制药”）；仿制药，简化新药申请（ANDA） 行业指南：ANDA提交——ANDA的内容和格式；仿制药，简化新药申请（ANDA） 橙皮书前言；仿制药，简化新药申请（ANDA） 专利认证和适宜性请愿；仿制药，简化新药申请（ANDA） 仿制药开发的产品特定指南 仿制药、简化新药申请（ANDA） 仿制药设施、场地和组织的自我认定 仿制药、简化新药申请（ANDA） ANDA前计划 仿制药、简化新药申请（ANDA）；会议、与FDA沟通 FDA授权仿制药清单 仿制药、简化新药申请（ANDA）；新药审评、新药申请（NDA） ANDA表格及提交要求 仿制药、简化新药申请（ANDA）；提交、表格、联系方式 受控通信 仿制药、简化新药申请（ANDA）；提交、表格、联系方式 GDUFA网络学习课程 仿制药、简化新药申请（ANDA）；用户费 仿制药用户费修正案（GDUFA） 仿制药、简化新药申请（ANDA）；用户费 出口证书 进出口、法规事务、国际项目 出口商信息 进出口、法规事务、国际项目 全球政策与战略办公室 进出口、法规事务、国际项目 法规事务办公室（ORA）目录 进出口、法规事务、国际项目；提交、表格、联系方式 扩大可及：行业信息 研究性新药申请（IND） 加速计划 研究性新药申请（IND） 探索性IND 研究性新药申请（IND） IND豁免 研究性新药申请（IND） 研究性新药（IND）申请研究性新药申请（IND） 研究者发起的IND及IND提交程序研究性新药申请（IND） 妊娠和哺乳期标签（药品）最终规则标签 FDA人用处方药标签资源标签 药品标签中的药物基因组学生物标志物表格标签 用药指南标签；数据库 顾问委员会（人用药品）会议，与FDA互动 药物开发期间IND申办者与FDA沟通的最佳实践会议，与FDA互动 在新药开发期间与FDA互动CDER学习课程会议，与FDA互动 人用药品新闻与活动会议，与FDA互动；关于FDA和CDER FDA与GDUFA下复杂产品ANDA申请人之间的正式会议——行业指南会议，与FDA互动；仿制药，简略新药申请（ANDA） IND前会议常见问题会议，与FDA互动；研究性新药申请（IND） FDA与BsUFA产品申办者或申请人之间的正式会议——行业指南会议，与FDA互动；生物制品，生物类似药，生物制品许可申请（BLA） FDA与PDUFA产品申办者或申请人之间的正式会议会议，与FDA互动；研究性新药申请（IND）；新药审评，新药申请（NDA） 新药申请（NDA）资源新药审评，新药申请（NDA） 申请预分配申请编号新药审评，新药申请（NDA） 第505(b)(2)条所涵盖的申请——行业指南 新药审评，新药申请（NDA）；试验用新药申请（IND） 处方药使用者付费修正案（PDUFA） 新药审评，新药申请（NDA）；使用者费用 药品和生物制品使用者费用豁免、减免和退还——行业指南 新药审评，新药申请（NDA）；使用者费用 非处方（OTC）药品的开发与监管 非处方药审评 非处方药药品申请 非处方药审评 非处方药专论与规则制定 非处方药审评 非处方药（OTC）专论程序 非处方药审评 非处方药专论使用者付费计划（OMUFA） 非处方药审评；使用者费用 现行药品生产质量管理规范（CGMP）法规 药品质量与生产 药品质量抽样和检测项目 药品质量与生产 有效期——问答 药品质量与生产 关于CGMP的事实 药品质量与生产 药品质量资源 药品质量与生产 药品生产的质量指标 药品质量与生产 关于CGMP的问与答 药品质量与生产 关于现行药品生产质量管理规范的问答——组分及药品容器和密封件的控制 药品质量与生产 现行药品生产质量管理规范问答——生产和工艺控制 药品质量与生产 报告产品质量问题 药品质量与生产 现行药品生产质量管理规范（CGMP）法规 药品质量与生产；法规、法律、指南 处方药促销办公室（OPDP） 上市后活动与促销 真实的处方药广告与促销（不良广告计划） 上市后活动与促销 患者和医务人员用上市后药品安全信息 上市后活动与促销；药物安全 上市后监测计划 上市后活动与促销；药物安全 开发用于罕见疾病和病症的产品 罕见疾病与孤儿药 关于指定孤儿产品的常见问题（FAQ） 罕见疾病与孤儿药 检索孤儿药指定和批准 罕见疾病与孤儿药 CDER Direct：电子提交门户 注册与登记 电子药品注册与登记说明 注册与登记 药品机构当前注册网站（DECRS数据库） 注册与登记；数据库 已注册外包设施（配制） 注册与登记；数据库 联邦法规汇编第21篇 法规、法律、指南 联邦食品、药品和化妆品法案 法规、法律、指南 法律、法规和指南 法规、法律、指南 检索FDA指南文件 法规、法律、指南 CDER报告与预算报告 应用监管科学部门年度报告 报告 药物与生物制品批准及IND活动报告 报告 快速通道批准报告 报告 GDUFA科学与研究报告 报告 IND申请报告：安全报告 报告 NDA与BLA批准报告 报告 NDA与BLA日历年批准报告 报告 临床药理学办公室年度报告 报告 仿制药办公室年度报告 报告 新药办公室年度报告 报告 药品质量办公室年度报告 报告 CDER数据标准项目 提交、表格、联系人 CDER Direct NextGen协作门户 提交、表格、联系人 CDER Direct NextGen协作门户常见问题解答 提交、表格、联系人 电子监管提交与审阅 提交、表格、联系人 FDA表格 提交、表格、联系人
正文 · 英文原文
Search for Regulatory References | Drugs CDER Small Business & Industry Assistance (SBIA) About CDER Small Business and Industry Assistance (SBIA) CDER SBIA Learn Search for Regulatory References | Drugs CDER SBIA On-Demand Learning Library Use filter and search box to find regulatory resources Topic About FDA and CDERBiologics, Biosimilars, Biologics License Application (BLA)Clinical Trials, Drug Development and ApprovalCompliance, Inspections, EnforcementCompoundingDatabasesDrug Master FilesDrug Safety, RecallsDrug Supply ChainGeneric Drugs, Abbreviated New Drug Application (ANDA)Import/Export, Regulatory Affairs, International ProgramsInvestigational New Drug Application (IND)LabelingMeetings, Engaging with FDANew Drug Review, New Drug Application (NDA)Over-the-Counter Drug ReviewPharmaceutical Quality and ManufacturingPost-Marketing Activities and PromotionRare Diseases and Orphan DrugsRegistration and ListingRegulations, Laws, GuidancesReportsSubmissions, Forms, ContactsTraining ResourcesUser Fees Clear Filter NameTopics Supply ChainDrug Supply Chain Search for Pharmaceutical Quality DocumentsPharmaceutical Quality and Manufacturing Multiple Endpoints Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Ethical Considerations for Clinical Investigations Involving Children -Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Neonatal Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Patient-Focused Drug Development Clinical Outcome Assessments Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Food Effects Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Bioavailability Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Population Pharmacokinetics Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Pathology Peer Review Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Benefit-Risk Assessment for New Drug and Biologic Products SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Adjusting for Covariates Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval In Vitro Drug Interaction Studies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Clinical Drug Interaction Studies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Complex Innovative Trial Designs Guidance SnapshotRegulations, Laws, Guidances; Meetings, Engaging with FDA Maximal Usage Trials Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Targeted Therapies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Multiple Endpoints Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Ethical Considerations for Clinical Investigations Involving Children -Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Neonatal Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Patient-Focused Drug Development Clinical Outcome Assessments Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Food Effects Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Bioavailability Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Population Pharmacokinetics Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Pathology Peer Review Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Adjusting for Covariates Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval In Vitro Drug Interaction Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Clinical Drug Interaction Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and Approval Complex Innovative Trial Designs Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Meetings, Engaging with FDA Complex Generics NewsGeneric Drugs, Abbreviated New Drug Applications Emerging Technology ProgramPharmaceutical Quality and Manufacturing Oncology Regulatory Expertise and Early Guidance (OREEG)Clinical Trials, Drug Development and Approval, Investigational New Drug Development Application (IND), Meetings, Engaging with FDA OTC Monographs@FDAOver-the-Counter Drug Review Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES ActOver-the-Counter Drug Review Phonetic and Orthographic Computer Analysis (POCA) ProgramDrug Safety; Clinical Trials, Drug Development and Approval About CDER Small Business and Industry AssistanceAbout FDA and CDER About FDAAbout FDA and CDER CDER Exclusivity BoardAbout FDA and CDER CDER OmbudsmanAbout FDA and CDER Doing Business With FDAAbout FDA and CDER Jobs at FDAAbout FDA and CDER Biosimilar Development, Review, and ApprovalBiologics, Biosimilars, Biologics License Application (BLA) Biosimilar Product Information (FDA-Approved List of Biological Products)Biologics, Biosimilars, Biologics License Application (BLA) BiosimilarsBiologics, Biosimilars, Biologics License Application (BLA) Biosimilars Action PlanBiologics, Biosimilars, Biologics License Application (BLA) Bisoimilar Industry Information and GuidanceBiologics, Biosimilars, Biologics License Application (BLA) "Deemed to be a License Provision" of the BPCI ActBiologics, Biosimilars, Biologics License Application (BLA) Frequently Asked Questions About Therapeutic Biological ProductsBiologics, Biosimilars, Biologics License Application (BLA) Therapeutic Biologic Applications (BLA) Approval InformationBiologics, Biosimilars, Biologics License Application (BLA) Transfer of Therapeutic Products to CDER Biologics, Biosimilars, Biologics License Application (BLA) Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability EvaluationsBiologics, Biosimilars, Biologics License Application (BLA); Databases Biosimilar User Fee Amendments (BsUFA)Biologics, Biosimilars, Biologics License Application (BLA); User Fees Biomarker Qualification ProgramClinical Trials, Drug Development and Approval Combination Products Clinical Trials, Drug Development and Approval Clinical Trials and Human Subject ProtectionClinical Trials, Drug Development and Approval Development & Approval ProcessClinical Trials, Drug Development and Approval Drug Development and Drug Interactions: Table of Substrates, Inhibitors and InducersClinical Trials, Drug Development and Approval Drug Development ProcessClinical Trials, Drug Development and Approval The FDA's Drug Review Process: Ensuring Drugs Are Safe and EffectiveClinical Trials, Drug Development and Approval Economic Assistance and Incentives for Drug DevelopmentClinical Trials, Drug Development and Approval Coronavirus (COVID-19)Clinical Trials, Drug Development and Approval COVID MyStudies Application (App)Clinical Trials, Drug Development and Approval Frequently Asked Questions on Patents and ExclusivityClinical Trials, Drug Development and Approval Real-World EvidenceClinical Trials, Drug Development and Approval Compliance Actions and ActivitiesCompliance, Inspections, Enforcement Inspections, Compliance, Enforcement, and Criminal InvestigationsCompliance, Inspections, Enforcement Unapproved DrugsCompliance, Inspections, Enforcement Warning Letters and Notice of Violation Letters to Pharmaceutical CompaniesCompliance, Inspections, Enforcement Compounding and the FDA: Questions and AnswersCompounding Compounding Risk AlertsCompounding Compounding: Inspections, Recalls, and other ActionsCompounding Human Drug CompoundingCompounding Drug Approvals and DatabasesDatabases Drugs@FDADatabases FDALabelDatabases Inactive Ingredient DatabaseDatabases National Drug Code DirectoryDatabases Drug ShortagesDatabases Search List of Extended Use Dates to Assist with Drug ShortagesDatabases Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)Databases; Generic Drugs, Abbreviated New Drug Application (ANDA) Drug Master File webpageDrug Master Files Drug Master Files: GuidelinesDrug Master Files Type II DMFs for Active Pharmaceutical IngredientsDrug Master Files Types of Drug Master Files (DMFs)Drug Master Files Drug RecallsDrug Safety, Recalls Drug Safety CommunicationsDrug Safety, Recalls FDA Adverse Event Reporting System (FAERS) Public DashboardDrug Safety, Recalls MedwatchDrug Safety, Recalls Preventable Adverse Drug Reactions: A Focus on Drug InteractionsDrug Safety, Recalls Risk Evaluation and Mitigation Strategies (REMS)Drug Safety, Recalls Drug Safety Labeling ChangesDrug Safety, Recalls; Labeling FDA Adverse Event Reporting System (FAERS) Electronic SubmissionsDrug Safety, Recalls; Submissions, Forms, Contacts Medwatch Reporting for IndustryDrug Safety, Recalls; Submissions, Forms, Contacts Drug Safety and AvailabilityDrug Safety; Databases Drug Supply Chain IntegrityDrug Supply Chain Drug Supply Chain Security ActDrug Supply Chain Verify Wholesale Drug Distributor LicensesDrug Supply Chain Abbreviated New Drug Application (ANDA)Generic Drugs, Abbreviated New Drug Application (ANDA) Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for IndustryGeneric Drugs, Abbreviated New Drug Application (ANDA) Dissolution Methods DatabaseGeneric Drugs, Abbreviated New Drug Application (ANDA) First Generic Drug ApprovalsGeneric Drugs, Abbreviated New Drug Application (ANDA) Generic Drug Research-Related Guidances and ReportsGeneric Drugs, Abbreviated New Drug Application (ANDA) Generic Drugs: Information for IndustryGeneric Drugs, Abbreviated New Drug Application (ANDA) Guidance Documents for Generic Drugs (search Generics under topic)Generic Drugs, Abbreviated New Drug Application (ANDA) Guidance for Industry: ANDA Submission - Content and Format of ANDAsGeneric Drugs, Abbreviated New Drug Application (ANDA) Orange Book PrefaceGeneric Drugs, Abbreviated New Drug Application (ANDA) Patent Certifications and Suitability PetitionsGeneric Drugs, Abbreviated New Drug Application (ANDA) Product-Specific Guidances for Generic Drug DevelopmentGeneric Drugs, Abbreviated New Drug Application (ANDA) Self-Identification of Generic Drug Facilities, Sites and OrganizationsGeneric Drugs, Abbreviated New Drug Application (ANDA) Pre-ANDA ProgramGeneric Drugs, Abbreviated New Drug Application (ANDA); Meetings, Engaging with FDA FDA List of Authorized Generic DrugsGeneric Drugs, Abbreviated New Drug Application (ANDA); New Drug Review, New Drug Application (NDA) ANDA Forms and Submissions RequirementsGeneric Drugs, Abbreviated New Drug Application (ANDA); Submissions, Forms, Contacts Controlled CorrespondenceGeneric Drugs, Abbreviated New Drug Application (ANDA); Submissions, Forms, Contacts GDUFA web-based learning coursesGeneric Drugs, Abbreviated New Drug Application (ANDA); User Fees Generic Drug User Fee Amendments (GDUFA)Generic Drugs, Abbreviated New Drug Application (ANDA); User Fees Export certificatesImport/Export, Regulatory Affairs, International Programs Information for ExportersImport/Export, Regulatory Affairs, International Programs Office of Global Policy and StrategyImport/Export, Regulatory Affairs, International Programs Office of Regulatory Affairs (ORA) Directory Import/Export, Regulatory Affairs, International Programs; Submissions, Forms, Contacts Expanded Access: Information for IndustryInvestigational New Drug Application (IND) Expedited ProgramsInvestigational New Drug Application (IND) Exploratory INDsInvestigational New Drug Application (IND) IND ExemptionsInvestigational New Drug Application (IND) Investigational New Drug (IND) ApplicationInvestigational New Drug Application (IND) Investigator-Initiated INDs and IND submission proceduresInvestigational New Drug Application (IND) Pregnancy and Lactation Labeling (Drugs) Final RuleLabeling FDA’s Labeling Resources for Human Prescription DrugsLabeling Table of Pharmacogenomic Biomarkers in Drug LabelingLabeling Medication GuidesLabeling; Databases Advisory Committees (human drugs)Meetings, Engaging with FDA Best Practices for Communication Between IND Sponsors and FDA During Drug DevelopmentMeetings, Engaging with FDA Engaging with FDA during New Drug Development CDERLearn CourseMeetings, Engaging with FDA News & Events for Human DrugsMeetings, Engaging with FDA; About FDA and CDER Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for IndustryMeetings, Engaging with FDA; Generic Drugs, Abbreviated New Drug Application (ANDA) Pre-IND Meeting FAQs Meetings, Engaging with FDA; Investigational New Drug Application (IND) Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for IndustryMeetings, Engaging with FDA; Biologics, Biosimilars, Biologics License Application (BLA) Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Meetings, Engaging with FDA; Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA) New Drug Application (NDA) ResourcesNew Drug Review, New Drug Application (NDA) Requesting a Pre-Assigned Application numberNew Drug Review, New Drug Application (NDA) Applications Covered by Section 505(b)2) Guidance for IndustryNew Drug Review, New Drug Application (NDA); Investigational New Drug Application (IND) Prescription Drug User Fee Amendments (PDUFA)New Drug Review, New Drug Application (NDA); User Fees User Fee Waivers, Reduction, and Refunds for Drug and Biological Products - Guidance for IndustryNew Drug Review, New Drug Application (NDA); User Fees Development and Regulation of OTC (Nonprescription) DrugsOver-the-Counter Drug Review Drug applications for OTC drugsOver-the-Counter Drug Review OTC Monographs and RulemakingOver-the-Counter Drug Review Over-the-Counter (OTC) Drug Monograph ProcessOver-the-Counter Drug Review Over-the-Counter Monograph User Fee Program (OMUFA)Over-the-Counter Drug Review; User Fees Current Good Manufacturing Practice (CGMP) RegulationsPharmaceutical Quality and Manufacturing Drug Quality Sampling and Testing ProgramsPharmaceutical Quality and Manufacturing Expiration Dates - Questions and AnswersPharmaceutical Quality and Manufacturing Facts About CGMPsPharmaceutical Quality and Manufacturing Pharmaceutical Quality Resources Pharmaceutical Quality and Manufacturing Quality Metrics for Drug ManufacturingPharmaceutical Quality and Manufacturing Questions and Answers on CGMPsPharmaceutical Quality and Manufacturing Questions and Answers on Current Good Manufacturing Practices—Control of Components and Drug Product Containers and ClosuresPharmaceutical Quality and Manufacturing Questions and Answers on Current Good Manufacturing Practices—Production and Process ControlsPharmaceutical Quality and Manufacturing Report a Product Quality IssuePharmaceutical Quality and Manufacturing Current Good Manufacturing Practice (CGMP) RegulationsPharmaceutical Quality and Manufacturing; Regulations, Laws, Guidances Office of Prescription Drug Promotion (OPDP)Post-Marketing Activities and Promotion Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)Post-Marketing Activities and Promotion Postmarket Drug Safety Information for Patients and ProvidersPost-Marketing Activities and Promotion; Drug Safety Postmarketing Surveillance ProgramsPost-Marketing Activities and Promotion; Drug Safety Developing Products for Rare Diseases and ConditionsRare Diseases and Orphan Drugs Frequently Asked Questions (FAQ) About Designating an Orphan ProductRare Diseases and Orphan Drugs Search Orphan Drug Designations and ApprovalsRare Diseases and Orphan Drugs CDER Direct: Electronic Submissions PortalRegistration and Listing Electronic Drug Registration and Listing InstructionsRegistration and Listing Drug Establishments Current Registration Site (DECRS Database)Registration and Listing; Databases Registered Outsourcing Facilities (Compounding)Registration and Listing; Databases Code of Federal Regulations, Title 21Regulations, Laws, Guidances Federal Food Drug & Cosmetic ActRegulations, Laws, Guidances Laws, Regulations and GuidancesRegulations, Laws, Guidances Search for FDA Guidance DocumentsRegulations, Laws, Guidances CDER Reports & BudgetReports Division of Applied Regulatory Science Annual ReportsReports Drug and Biologic Approval and IND Activity ReportsReports Fast Track ApprovalsReports GDUFA Science and Research ReportsReports IND Application Reporting: Safety ReportsReports NDA and BLA ApprovalsReports NDA and BLA Calendar Year ApprovalsReports Office of Clinical Pharmacology Annual ReportsReports Office of Generic Drugs Annual ReportsReports Office of New Drugs Annual ReportsReports Office of Pharmaceutical Quality Annual ReportsReports CDER Data Standards ProgramSubmissions, Forms, Contacts CDER Direct NextGen Collaboration PortalSubmissions, Forms, Contacts CDER Direct NextGen Collaboration Portal FAQsSubmissions, Forms, Contacts Electronic Regulatory Submission and ReviewSubmissions, Forms, Contacts FDA FormsSubmissions, Forms, Conta